MEDICAL RADIOLOGICAL DEFENSE (SDD)
Abstract
This project funds the advanced development of candidate therapeutic medical countermeasures to mitigate the consequences of exposure to ionizing radiation from nuclear or radiological attacks. Exposure to ionizing radiation causes damage to blood-forming cells (hematopoietic system) and gastrointestinal system, leading to Acute Radiation Syndrome (ARS). Medical countermeasures must be approved by the Food and Drug Administration (FDA) for human use prior to fielding. Testing the efficacy of candidate drugs against lethal radiation exposure cannot be conducted in humans; therefore, surrogate animal models must be used to obtain FDA approval. Medical Radiological Countermeasures (MRADC) efforts include multiple countermeasures required to protect U.S. Forces against injury caused by exposure to radiation and to restore casualties to pre-exposure health. MRADC shall reverse or limit radiation injury resulting in increased survival, decreased incapacity, and sustained operational effectiveness. In addition, MRADC shall be effective against a broad range of radiation sources and types and shall be useable throughout the full spectrum of healthcare operations.
Document Details
- Document Type
- Project
- Publication Date
- Oct 01, 2012
- Source ID
- MR5_0604384BP_5_0400_PB_2012
Related Documents
- Root: CHEMICAL/BIOLOGICAL DEFENSE (SDD)
- Child Accomplishment: 1) MRADC
- Child Accomplishment: 2) MRADC
- Child Cost Item: a5019a396b83abd6d8cb04f26d09c1ef
- Child Cost Item: 6aeebf16924edb629288f5e06941b78a
- Child Cost Item: ad45c8bc9f6c3f1ffc6b648a0b8735c2
- Child Cost Item: 59b7e6ac8ef69a3191d5a9b570447900